International Stem Cell (ISCO) Retained Earnings (2010 - 2026)

International Stem Cell (ISCO) has reported Retained Earnings for 17 consecutive years, with -$111.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Retained Earnings fell 0.53% year-over-year to -$111.4 million in Q2 2026; TTM through Jun 2026 was -$111.4 million, a 0.53% decrease from a year earlier, with the FY2025 full-year figure at -$111.1 million, changed 0.38% from the prior year.
• Retained Earnings was -$111.4 million for Q2 2026 at International Stem Cell, roughly flat from -$111.1 million in the prior quarter.
• Over five years, Retained Earnings peaked at -$109.9 million in Q2 2023 and troughed at -$111.4 million in Q2 2026.
• A 5-year average of -$110.5 million and a median of -$110.6 million in 2024 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings dropped 0.64% in 2022 and climbed 0.35% in 2023, its largest moves.
• Over 5 years, Retained Earnings stood at -$110.3 million in 2022, then retreated by 0.12% to -$110.5 million in 2023, then slipped by 0.19% to -$110.7 million in 2024, then slipped by 0.38% to -$111.1 million in 2025, then retreated by 0.27% to -$111.4 million in 2026.
• The last three Retained Earnings figures came in at -$111.4 million (Q2 2026), -$111.1 million (Q4 2025), and -$110.8 million (Q3 2025), per Business Quant data.